Scientists Develop New Treatment Option for Multidrug-Resistant Infections
06 June 2019
Tebipenem pivoxil hydrobromide (SPR994)is a new carbapenem being developed by Spero Therapeutics that is being developed as an oral antimicrobial agent. Such a treatment may facilitate earlier discharge from hospital or the possibility of treating complex infections in the community.
Further reading: Infection Control Today
Smart Innovations
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
 |
BD |
AMR NEWS
Every two weeks in your inbox
Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!